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Abstract: Treatment of invasive infections caused by Candida auris is challenging due to the limited
therapeutic options. The combination of antifungal drugs may be an interesting and feasible approach
to be investigated. The aim of this study was to examine the in vitro activity of amphotericin B in
combination with anidulafungin or caspofungin against C. auris. In vitro static time–kill curve exper-
iments were conducted for 48 h with different combinations of amphotericin B with anidulafungin or
caspofungin against six blood isolates of C. auris. The antifungal activity of 0.5 mg/L of amphotericin
B was limited against the six isolates of C. auris. Similarly, echinocandins alone had a negligible
effect, even at the highest tested concentrations. By contrast, 1 mg/L of amphotericin B showed
fungistatic activity. Synergy was rapidly achieved (8 h) with 0.5 mg/L of amphotericin B plus 2 mg/L
of anidulafungin or caspofungin. These combinations lead to a sustained fungistatic effect, and the
fungicidal endpoint was reached against some C. auris isolates. Additionally, ≥0.5 mg/L of either of
the two echinocandins with 1 mg/L of amphotericin B resulted in fungicidal effect against all C. auris
isolates. In conclusion, combinations of amphotericin B with anidulafungin or caspofungin provided
greater killing with a lower dose requirement for amphotericin B compared to monotherapy, with
synergistic and/or fungicidal outcomes.
Keywords: Candida auris; combination; antifungal agents; amphotericin B; echinocandins; anidula-
fungin; caspofungin; time-kill
1. Introduction
Candida auris is a multi-drug resistant fungal pathogen, responsible for several cases
of invasive fungemia since 2009, that has become a global public concern [1,2]. In contrast
to what has been observed for other species of Candida, where resistance to antifungal
drugs are exceptions, in the case of C. auris, both intrinsic and acquired resistance are the
norm [3,4]. C. auris shows high rates of resistance to fluconazole and other azoles, along
with a reduced susceptibility to amphotericin B and echinocandins that complicate the
therapeutic approaches for candidiasis caused by this species [5,6]. Additionally, cross-
and multi-resistance has been found in 18–41% of C. auris isolates and approximately 4%
of them are resistant to the three main classes antifungal drugs: polyenes, azoles, and
echinocandins [7,8]. Even echinocandins (anidulafungin, caspofungin, and micafungin) are
nowadays considered the first-line therapeutic option to treat C. auris infections, therapeutic
failures often occur in critically ill patients. It has been evidenced that echinocandins
are not fungicidal against C. auris clinical isolates representing the four identified main
clades [9,10]. Against a background of increasing evidence of limited susceptibility of
C. auris to available antifungal agents in monotherapy, the approach of combining drugs
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with different antifungal mechanisms has been proposed to optimize the therapeutic
management of invasive mycoses.
Echinocandins act as non-competitive inhibitors of β-(1,3)-D-glucan synthase, in-
volved in the biosynthesis of β-(1,3)-D-glucan in the fungal cell wall. Amphotericin B binds
to ergosterol, forming pores and disrupting fungal cell membrane. It has been demon-
strated that amphotericin B exhibits in vitro fungicidal activity against C. auris, albeit at
high concentrations [9]. Recent studies included combinations of azoles, echinocandins,
amphotericin B, and flucytosine, with disparate results of indifference or synergy, de-
pending on the combined drugs and tested isolates of C. auris [11–14]. In this line, the
in vitro combinations of echinocandins and isavuconazole against C. auris have shown syn-
ergism [15,16]. Hence, the combinations of the first-line echinoncadins with the fungicidal
agent amphotericin B against C. auris deserves to be investigated.
The aim of the current study was to examine the in vitro activity of the combination
of amphotericin B with anidulafungin or caspofungin, against C. auris. To our knowl-
edge, this is the first study that has investigated the combination of amphotericin B with
echinocandins against this pathogen using time-kill curves.
2. Materials and Methods
Six blood isolates of C. auris (CJ94, CJ97, CJ98, CJ99, CJ100, and CJ102) collected from
different patients from an invasive candidiasis outbreak in the Hospital Universitario
y Politécnico La Fé (Valencia, Spain) were studied [17]. The isolates of the study were
phylogenetically close to the South African clade isolates [17,18]. The C. auris blood isolates
used in this study were non-aggregating isolates, as it was previously demonstrated
in vitro [19]. Fungal strains were stored in vials with sterile distilled water and cultivated
in Sabouraud dextrose agar (SDA), as previously described [14]. MICs were determined
following EUCAST E.DEF 7.3 document [20]. MICs for amphotericin B, anidulafungin,
and caspofungin were 1, 0.125, and 0.25 mg/L, respectively, for all isolates.
Amphotericin B (Sigma-Aldrich, Madrid, Spain), anidulafungin (Pfizer SLU, Madrid,
Spain), and caspofungin (Merck Sharp and Dohme, Madrid, Spain) were obtained in
powder, dissolved in dimethyl sulfoxide (DMSO) to obtain stock solutions of 3200 mg/L
and maintained at −80 ◦C until use.
Time–kill assays were carried out as previously described in a 96-well flat-bottomed
microtiter plates, in RPMI medium, and by using an inoculum size of 1–5 × 105 colony
forming units (CFU/mL) [15]. Antifungal drug concentrations assayed were selected on
the basis of previous time–kill and checkerboard results (unpublished data). Accordingly,
0.5 mg/L of amphotericin B was combined with 0.5, 1, and 2 mg/L of each echinocandin,
and 1 mg/L of amphotericin B was combined with 0.25, 0.5, and 1 mg/L of echinocandin.
Aliquots were collected at 0, 2, 4, 6, 8, 24, and 48 h for colony counts, plated onto SDA
in triplicate and incubated at 37 ◦C for 24 to 48 h. Depending on the drug concentration
and expected activity, samples were either first diluted in PBS (no antifungal activity) or
plated directly (5–20 µL). When a sterilizing activity was expected, the whole well (200 µL)
was sampled onto a SDA plate. Therefore, the lower limit of detectable colony counts
was 5 CFU/mL. The carryover effect was determined as previously described [21]. All
experiments were conducted twice. Fungistatic or fungicidal activities were defined as a
<3 log or ≥3 log reduction in CFU/mL, respectively. Synergism was defined as a difference
of >2 log between the activity of the drugs in combination and the activity of the most
active agent in monotherapy [22].
Time–kill curves were analysed as described previously [15], by fitting the CFU/mL
observations to an exponential equation: Nt = N0 × ekt (Nt, number of CFU/mL at time
t; N0, starting inoculum; k, growing or killing rate constant, and t, incubation time). This
equation was linearized by applying natural logarithms, and k values were then used to
compare the killing activities among drugs and concentrations. Positive killing rate (k)
values indicate growth, and negative values show killing. Thus, the seven time-points on
each killing curve were reduced to one k value (mean values). Goodness of fit for each
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combination was assessed by the r2 value (≥0.8). Significant differences in killing kinetics
among combinations and concentrations were evaluated by ANOVA with Bonferroni’s
post-testing (GraphPad Prism 5.01). A p value < 0.05 was considered significant.
3. Results
Mean time–kill curves for all isolates and combinations are shown in Figure 1. No
antifungal carryover was observed. Fungal counts at 8, 24, and 48 h for each isolate and
combination are depicted in Table 1. The antifungal activity of amphotericin B alone at the
concentration of 0.5 mg/L was limited against the six isolates of C. auris, as no fungicidal nor
fungistatic effect was achieved. Similarly, echinocandins alone had a negligible effect, even
at the highest tested concentrations. In contrast to the poor results of the monotherapies,
the combination of 0.5 mg/L of amphotericin B with anidulafungin or caspofungin led
to a sustained fungistatic effect, and the fungicidal endpoint was reached against isolates
C. auris CJ94, C. auris CJ99, C. auris CJ100, and C. auris CJ102. The interactions were
synergistic from 24 h onwards for all isolates and concentrations. Conversely, 1 mg/L of
amphotericin B showed fungistatic activity, and the combinations of this polyene with
the echinocandins were mostly additive. Regardless of the additivity detected, when
≥0.5 mg/L of echinocandin was combined with 1 mg/L of amphotericin B, fungicidal
effect was achieved against all isolates.
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and caspofungin; (c) 1 mg/L of amphotericin B and anidulafungin; ( ) 1 mg/L of amphotericin B and casp fungi . Data
are plotted as average data points from the different isolates ± standard error (SE). Antifung l rug c ncentrations
expressed in mg/L. AmB, amphotericin B.
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Table 1. Fungal counts at 8, 24, and 48 h and interaction classification.
AmB+ECH
(mg/L)
Fungal Count (log CFU/mL) (SD)
AmB+ANF AmB+CSP
8 h 24 h 48 h 8 h 24 h 48 h
CJ94 Control 6.68 (0.26) 7.65 (0.08) 7.83 (0.10) 6.68 (0.26) 7.65 (0.10) 7.83 (0.10)
0.5 AMB 5.14 (0.29) 6.58 (0.43) 7.37 (0.14) 5.14 (0.29) 6.58 (0.43) 7.37 (0.14)
0.5+0.5 4.52 (0.26) 3.91 (0.05) 3.62 (0.58) 4.62 (0.07) 4.36 (0.40) 5.26 (0.10)
0.5+1 3.73 (0.31) 3.72 (0.31) 2.86 (0.66) 4.10 (0.00) 3.22 (0.25) 3.96 (0.51)
0.5+2 2.92 (0.16) 1.10 (1.55) 1.07 (1.51) 2.98 (0.30) 3.21 (0.45) 3.20 (0.08)
1 AMB 4.03 (0.23) 3.40 (0.21) 2.52 (0.06) 4.03 (0.23) 3.40 (0.20) 2.52 (0.06)
1+0.25 3.15 (0.49) 2.90 (0.71) 1.35 (0.21) 3.12 (0.17) 2.37 (0.11) 2.68 (0.19)
1+0.5 3.13 (0.18) 2.21 (0.17) 0.84 (1.19) 3.07 (0.10) 2.60 (0.69) 1.71 (1.39)
1+1 2.87 (0.03) 2.66 (0.04) 1.71 (0.56) 2.50 (0.14) 2.09 (0.84) 2.62 (0.12)
CJ97 Control 6.20 (0.00) 7.62 (0.06) 7.71 (0.3) 6.20 (0.00) 7.63 (0.06) 7.71 (0.30)
0.5 AMB 5.23 (0.05) 6.81 (0.04) 7.32 (0.00) 5.23 (0.05) 6.81 (0.04) 7.32 (0.00)
0.5+0.5 4.67 (0.00) 4.21 (0.02) 3.54 (0.18) 4.65 (0.02) 4.29 (0.66) 4.08 (0.36)
0.5+1 3.65 (0.07) 3.32 (0.04) 2.77 (0.54) 3.98 (0.02) 3.47 (0.16) 2.52 (0.11)
0.5+2 3.08 (0.39) 2.49 (0.86) 2.44 (2.39) 3.31 (0.25) 3.20 (0.29) 3.40 (0.22)
1 AMB 4.42 (0.32) 4.16 (1.03) 3.20 (0.69) 4.43 (0.32) 4.17 (1.00) 3.20 (0.69)
1+0.25 3.68 (0.25) 2.72 (0.22) 2.63(1.99) 3.52 (0.17) 3.07 (0.04) 2.48 (0.70)
1+0.5 3.30 (0.00) 3.28 (0.47) 0.50 (0.70) 3.45 (0.21) 2.44 (0.22) 1.76 (1.00)
1+1 2.83 (0.14) 2.87 (1.37) 2.09 (0.84) 2.17 (0.17) 2.43 (0.21) 2.37 (3.35)
CJ98 Control 6.38 (0.02) 7.54 (0.01) 7.95 (0.09) 6.38 (0.02) 7.54 (0.01) 7.95 (0.08)
0.5 AMB 5.20 (0.05) 6.40 (0.40) 7.50 (0.16) 5.23 (0.05) 6.4 (0.43) 7.48 (0.16)
0.5+0.5 4.42 (0.20) 3.79 (0.39) 3.55 (0.14) 4.38 (0.16) 3.96 (0.22) 5.08 (1.17)
0.5+1 3.35 (0.02) 3.03 (0.37) 3.00 (1.00) 3.55 (0.44) 3.22 (0.49) 1.85 (0.21)
0.5+2 2.86 (0.05) 3.23 (0.78) 3.39 (1.12) 2.73 (0.05) 2.48 (0.05) 3.52 (1.03)
1 AMB 3.85 (0.07) 3.61 (0.48) 3.77 (0.46) 3.85 (0.07) 3.61 (0.48) 3.77 (0.46)
1+0.25 3.13 (0.28) 2.55 (0.40) 1.79 (0.49) 2.95 (0.12) 2.57 (0.13) 3.60 (0.73)
1+0.5 3.06 (0.09) 2.39 (0.80) 1.79 (1.40) 3.00 (0.01) 3.31 (0.59) 1.00 (0.01)
1+1 2.26 (0.15) 3.22 (2.00) 0.60 (0.84) 1.3 (0.42) 1.97 (2.78) 0.00 (0.00)
CJ99 Control 6.88 (0.44) 7.54 (0.04) 7.93 (0.09) 6.88 (0.44) 7.54 (0.04) 7.93 (0.09)
0.5 AMB 5.30 (0.37) 7.05 (0.10) 7.54 (0.01) 5.30 (0.37) 7.05 (0.11) 7.54 (0.01)
0.5+0.5 4.68 (0.20) 4.68 (0.60) 3.28 (1.16) 4.70 (0.14) 3.94 (0.17) 3.19 (0.84)
0.5+1 3.88 (0.16) 2.68 (0.27) 3.11 (0.87) 3.75 (0.11) 2.84 (0.42) 1.68 (0.01)
0.5+2 2.58 (0.16) 1.7 (0.49) 2.40 (0.80) 2.66 (0.23) 2.69 (1.68) 3.40 (2.35)
1 AMB 3.88 (0.26) 2.99 (0.43) 4.93 (0.42) 3.88 (0.25) 2.99 (0.43) 4.94 (0.41)
1+0.25 2.90 (0.59) 2.23 (1.12) 1.77 (1.96) 3.10 (0.47) 1.99 (1.33) 1.43 (0.98)
1+0.5 2.90 (0.47) 2.29 (1.76) 1.91 (1.65) 2.38 (0.54) 2.06 (0.06) 1.90 (1.63)
1+1 2.25 (0.35) 2.23 (0.24) 0.95 (1.34) 2.25 (0.49) 2.19 (0.15) 0.00 (0.00)
CJ100 Control 6.43 (0.33) 7.7 (0.19) 7.81 (012) 6.43 (0.33) 7.70 (0.20) 7.80 (0.12)
0.5 AMB 5.50 (0.47) 7.28 (0.06) 7.49 (0.04) 5.50 (0.47) 7.28 (0.06) 7.49 (0.04)
0.5+0.5 4.55 (0.35) 4.72 (0.2) 4.32 (1.43) 4.55 (0.26) 4.78 (0.03) 3.26 (0.14)
0.5+1 3.02 (0.96) 2.65 (0.91) 2.29 (0.40) 3.82 (0.68) 2.75 (0.43) 1.42 (0.98)
0.5+2 2.66 (0.53) 2.25 (0.23) 1.74 (0.55) 2.70 (0.00) 2.93 (0.08) 2.09 (0.74)
1 AMB 4.17 (0.19) 3.34 (0.49) 3.10 (0.00) 4.16 (0.18) 3.34 (0.49) 3.10 (0.00)
1+0.25 2.96 (1.36) 2.38 (1.33) 1.07 (1.52) 3.02 (0.74) 2.67 (0.49) 2.10 (0.18)
1+0.5 3.20 (0.98) 2.45 (0.51) 2.1 (0.72) 2.88 (0.82) 1.23 (1.74) 0.53 (0.74)
1+1 2.61 (0.11) 1.37 (1.59) 1.73 (1.41) 1.80 (0.00) 0.00 (0.00) 0.00 (0.00)
CJ102 Control 6.52 (0.16) 7.59 (0.15) 7.59 (0.23) 6.52 (0.16) 7.59 (0.15) 7.6 0(0.24)
0.5 AMB 5.11 (0.21) 6.06 (0.12) 6.94 (0.57) 5.11 (0.21) 6.06 (0.13) 6.94 (0.57)
0.5+0.5 4.46 (0.18) 4.04 (0.40) 4.01 (0.15) 4.25 (0.16) 3.86 (0.16) 4.58 (0.48)
0.5+1 4.40 (0.14) 3.73 (0.09) 3.69 (0.43) 3.91 (0.02) 3.36 (0.01) 2.39 (0.00)
0.5+2 2.65 (0.35) 2.00 (0.25) 3.52 (0.00) 2.70 (0.14) 2.62 (0.52) 3.06 (0.00)
1 AMB 3.80 (0.14) 3.82 (0.44) 4.04 (0.19) 3.80 (0.14) 3.82 (0.43) 4.04 (0.18)
1+0.25 3.05 (0.44) 2.73 (0.36) 2.79 (1.14) 2.94 (0.27) 3.56 (0.51) 3.31 (0.00)
1+0.5 3.22 (0.40) 2.52 (0.84) 1.39 (0.52) 2.21 (0.50) 2.92 (1.10) 2.88 (0.10)
1+1 2.39 (0.06) 1.74 (1.02) 0.84 (1.18) 1.70 (0.70) 0.00 (0.00) 0.00 (0.00)
Synergy is marked in bold and fungicidal effects are underlined. AmB: amphotericin B; ECH: echinocandin; ANF: anidulafungin; CSP:
caspofungin.
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Interestingly, a quarter of all combination time–kill experiments showed regrowth
phenomena. The regrowth was observed specially for the combinations of 0.5 mg/L of
amphotericin B with 2 mg/L of echinocandin, which resulted, in the case of caspofungin,
in a lower mean effect compared to the combination that included 1 mg/L of caspofungin
(Figure 1).
When the killing-rate constants were analysed, positive k values, non-different from con-
trol curves, were obtained for all the drugs and concentrations in monotherapy (k = 0.055 h−1),
except for amphotericin B at 1 mg/L, with a negative mean k value (k = −0.031 h−1), indi-
cating fungal killing, even though the fungicidal threshold was not reached (Table 1). In
contrast to the positive k values for echinocandins alone, and for 0.5 mg/L of amphotericin
B, the time–kill curves patterns shifted for the combinations, all killing-rate constants were
negative and significantly different from monotherapy. This was also the case for the
combinations of anidulafungin with 1 mg/L of amphotericin B. Conversely, only the k of
the combination of 1 mg/L amphotericin B plus 1 mg/L of caspofungin was significantly
different from amphotericin B monotherapy. The reason may be due to the higher variabil-
ity observed in the activity of caspofungin in contrast to anidulafungin. Mean killing rate
constants for each drug combination are graphically represented in Figure 2.
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Figure 2. Mean killing-rate constant values for the combinations of amphotericin B and echinocandins against C. auris: (a) 
0.5 mg/L of amphotericin B and anidulafungin; (b) 0.5 mg/L of amphotericin B and caspofungin; (c) 1 mg/L of amphotericin 
B and anidulafungin; (d) 1 mg/L of amphotericin B and caspofungin Each data point represents the mean result ± standard 
deviation (error bars) of all isolates and replicates. * p < 0.05 vs. 0.5 mg/L AmB; # p < 0.05 vs. 1 mg/L AmB (One-way 
ANOVA followed by Bonferroni ś post hoc test). AmB, amphotericin B. 
4. Discussion 
Although echinocandins are the first-choice treatment for invasive candidiasis, the 
present study found that anidulafungin and caspofungin in monotherapy had no activity 
against any of the six C. auris isolates studied, while amphotericin B did, although at con-
centrations ≥ 1 μg/mL. Previously, we have reported that amphotericin B reached fungi-
cidal endpoint at concentrations ≥ 2 mg/L [23], in concordance with another study [9]. 
Thus far, there are only two works that have evaluated the activity of echinocandins 
against C. auris with this time–kill curve approach. In both studies, the first in vitro evi-
dence of the lack of fungicidal effect of the echinocandins was provided [9,10]. Dudiuk et 
al. reported that the average k values for caspofungin and anidulafungin were close to 
zero. Our results are similar, especially for caspofungin at 48 h, although the activity of 
anidulafungin in their study was higher, as they reported a fungistatic effect at 24 and 48 
h [9]. Kovács et al. investigated the killing activities of the three echinocandins against 
isolates from each C. auris clade. Their results were mostly in agreement with Dudiuk et 
al. and with those reported in the current study. They found fungistatic activity against 
the isolates from all clades [10]. Different possible explanations for the weak in vitro fun-
gistatic activity of echinocandins against C .auris have been proposed, such as the cell ag-
gregation formation as a survival strategy [10]. Szekely et al. observed the in vitro for-
mation of large cell aggregates in South African isolates [24], and other reports have also 
described this C. auris aggregative behaviour in vivo for most (up to 84%) isolates from 
the South African clade [25,26]. Interestingly, this aggregation was induced and reversible 
by echinocandin exposure, but not with amphotericin B exposure [24]. However, we have 
Figure 2. Mean killing-rate constant values for the combinations of amphotericin B and echinocandins against C. auris:
(a) 0.5 mg/L of amphotericin B and anidulafungin; (b) 0.5 mg/L of amphotericin B and caspofungin; (c) 1 mg/L of
amphotericin B and anidulafungin; (d) 1 mg/L of amphotericin B and caspofungin Each data point represents the mean
result ± standard deviation (error bars) of all isolates and replicates. * p < 0.05 vs. 0.5 mg/L AmB; # p < 0.05 vs. 1 mg/L
mB (One-way ANOVA followed by Bonferroni’s post hoc test). AmB, amphotericin B.
4. Discussion
Although echinocandins are the first-choice treatment for invasive candidiasis, the
present study found that anidulafungin and caspofungin in monotherapy had no activity
against any of the six C. auris isolates studied, while amphotericin B did, although at
concentrations ≥1 µg/mL. Previously, we have reported that amphotericin B reached
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fungicidal endpoint at concentrations ≥2 mg/L [23], in concordance with another study [9].
Thus far, there are only two works that have evaluated the activity of echinocandins
against C. auris with this time–kill curve approach. In both studies, the first in vitro
evidence of the lack of fungicidal effect of the echinocandins was provided [9,10]. Dudiuk
et al. reported that the average k values for caspofungin and anidulafungin were close
to zero. Our results are similar, especially for caspofungin at 48 h, although the activity
of anidulafungin in their study was higher, as they reported a fungistatic effect at 24 and
48 h [9]. Kovács et al. investigated the killing activities of the three echinocandins against
isolates from each C. auris clade. Their results were mostly in agreement with Dudiuk
et al. and with those reported in the current study. They found fungistatic activity against
the isolates from all clades [10]. Different possible explanations for the weak in vitro
fungistatic activity of echinocandins against C. auris have been proposed, such as the cell
aggregation formation as a survival strategy [10]. Szekely et al. observed the in vitro
formation of large cell aggregates in South African isolates [24], and other reports have also
described this C. auris aggregative behaviour in vivo for most (up to 84%) isolates from
the South African clade [25,26]. Interestingly, this aggregation was induced and reversible
by echinocandin exposure, but not with amphotericin B exposure [24]. However, we have
previously reported that isolates from our study related to the South African clade do not
grow as aggregates and are more pathogenic in vivo than other isolates that displayed an
aggregating phenotype [19]. This could be due to the fact that C. auris produces virulence
factor in a strain-dependent way, with different aggregating behaviour and virulence
among isolates within the same clade [25,26]. In fact, differences in murine virulence have
been reported for isolates from the same clade [26]. Nevertheless, regarding the clinical
relevance of the aggregating ability of certain C. auris isolates, further studies are needed to
determine if the aggregate formation during infection protects those strains from the effect
of antifungal drugs.
Additionally, it has been suggested that the aggregation may not be enough for C. auris
isolates to overcome echinocandin exposure [10], while other mechanisms have also been
proposed to explain the limited fungistatic activity of echinocandins, such as the increased
cell wall chitin as a response to the decrease in the amount of β-glucan induced by the
echinocandin exposure [27,28]. In this line, other reports found increased chitin amounts
in C. auris, compared to other species more susceptible to echinocandin drugs [29].
The lack of fungicidal activity found in vitro for echinocandins against C. auris, along
with the high concentrations of amphotericin B required to reach the fungicidal endpoint,
support the interest to examine the combinations with the two classes of antifungal agents.
In the current study it should be highlighted that synergy was rapidly achieved (8 h)
with the combinations of amphotericin B at 0.5 mg/L and the highest concentration of
anidulafungin or caspofungin (2 mg/L). Once achieved, synergy was sustained over 48 h.
Moreover, the combinations of amphotericin B at 1 mg/L and anidulafungin or caspofungin
resulted in a fungicidal activity. The achievement of this fungicidal activity and the earlier
arrival to this point was related to higher concentrations of echinocandins. The findings
of synergy, and in some cases of fungicidal activity, were promising, especially if the lack
of activity of the drugs alone (except for amphotericin B at the high concentration) is
considered.
To our knowledge, this is the first study on the combination of amphotericin B with
echinocandins against C. auris through in vitro time–kill curves. Very few studies have
examined the effect of antifungal drug combinations against this species, and most of
them have assessed the interactions solely with checkerboard data and fractional inhibitory
concentration index (FICI) determination. O’Brien et al. studied C. auris isolates from a
New York outbreak of candidiasis and found synergism for the combination of flucytosine
and echinocandins or amphotericin B, but not for the combination of amphotericin B
with echinocandins [13]. The New York strains that they evaluated were related to the
South Asian clade, while our isolates from the Valencia outbreak are related to the South
African clade. This different origin could explain the lack of concordance between both
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studies. However, Bidaut et al. observed indifference for the combination of amphotericin
B with flucytosine tested against C. auris isolates determined by FICI [12]. Published
works suggest that there might be differences in antifungal susceptibility among C. auris
clades [10,12]. Therefore, the synergism and antifungal activity shown by the combinations
of amphotericin B and anidulafungin or caspofungin in our study may not replicate in
isolates belonging to other clades.
Combination therapy with amphotericin B and echinocandins has been studied for
other species of Candida, with variable results. Kiraz et al. reported that amphotericin B
plus caspofungin showed synergism against 46% of the tested Candida glabrata isolates with
time—kill assays [30]. Another study found a similar degree of synergism with anidula-
fungin against various species of Candida [31]. Conversely, other studies with C. glabrata
demonstrated a lack of synergy with the combinations of amphotericin B and echinocan-
dins [32]. Although most interactions were deemed indifferent by the checkerboard method
in the study of Serena et al. on the combination of amphotericin B with micafungin, there
was synergism against some strains that were further analysed by time–kill methodology
and the combination demonstrated a fast-killing activity against them [33].
Olson et al. tested the combinations of amphotericin B and caspofungin or micafungin
in immunosuppressed mice infected with C. glabrata and found that both combinations,
administered either concomitantly or sequentially, significantly reduced the fungal burden
in tissues compared to any of the drugs in monotherapy [34]. Hossain et al. also reported a
significant fungal reduction with the co-administration of amphotericin B and caspofungin
against azole-resistant Candida albicans. However, when mice survival was checked, the
difference between combination therapy and monotherapy with amphotericin B was not
significant, even though the survival was higher in the drug combination group [35].
Clinical evidence regarding the combination of amphotericin B with echinocandins for
invasive candidiasis is scarce and mostly published as case reports. Mpakosi et al. reported
the successful treatment with liposomal amphotericin B and micafungin of a preterm
infant with Candida (Metschnikowia) pulcherrima fungaemia [36]. This rare species is, along
with C. auris, part of the Metschnikowiaceae family. Another report from Japan described
the eradication of Candida guillermondii infection in an oncology patient using the same
combination [37]. Roberts et al. reported a case of a patient suffering from C. auris intra-
articular infection successfully treated with amphotericin-impregnated spacer in addition
to systemic fluconazole or micafungin [38]. Apart from these case reports, there is limited
evidence on this issue, and the combined therapy of echinocandins with amphotericin B
has been used mostly in the treatment of invasive aspergillosis. Yilmaz et al. observed that
the combination of amphotericin B and caspofungin was safe and effective in the treatment
of invasive fungal infections of children with haematological malignancy, refractory to
amphotericin B, and caused by Aspergillus or Candida [39]. The multicentre observational
ProCAS study evaluated the effectiveness and safety of caspofungin in monotherapy and
in combination with amphotericin B or voriconazole in adult haematological patients with
invasive candidiasis. Favourable results were reported for Candida krusei fungemia treated
with amphotericin B plus caspofungin [40].
5. Conclusions
The combinations of amphotericin B with echinocandins provided greater killing
with a lower dose requirement of amphotericin B against all isolates of C. auris. These
findings could support a new therapeutic approach and expand the therapeutic options by
combining two first-line antifungal drugs in those cases where invasive candidiasis caused
by this species does not respond to current treatment. Despite the favourable results of the
combination, further in vivo studies are needed to better assess possible clinical relevance,
considering criteria of effectiveness and safety.
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